Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Children who have disabilities will be able to express their unique experiences like never before thanks to a first-of-its-kind app developed by Gillette Children’s Specialty Healthcare in St. Paul, Minnesota.
The app, an ability-themed emoji keyboard called Emojability, will allow families, patients, caregivers and advocates in the special needs community to communicate, support one another and feel empowered to celebrate the goals and successes they’ve achieved. From adaptive equipment and therapy emojis to words of encouragement, Emojability brings to life symbols and phrases that don’t exist on other emoji keyboards. The free app is now available for download on smartphones.
To view the multimedia release go to:
http://www.multivu.com/players/English/7823251-gillette-childrens-emojability/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Rosecrance, one of the country’s leading teen substance abuse treatment centers, has launched a traveling art exhibit to help parents understand teenagers’ points of view about pressures they encounter and how they are faced with the potential to use, and abuse, substances. Developed by teen patients participating in an art therapy program at Rosecrance’s adolescent campus in Rockford, IL, “In My Shoes” encourages parents to understand their teen’s point of view and actively parent to help teens navigate today’s confusing environment.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7348551-rosecrance-s-in-my-shoes-traveling-art-exhibit-parents-teenagers-prevent-substance-abuse/
Madison Taliaferro spent weeks in the hospital in 2012. After a decade of suffering from cystic fibrosis, she underwent a double lung transplant. She powered through the difficult surgery and the recovery that followed –long days of physical therapy and rehabilitation. Her parents were there. Her best friend visited from Kansas. Grandparents rotated shifts so she was never alone. But one request still lingered.
“I just wanted to see my dogs,” she remembers.
Having suffered from the effects of chronic illness for the decade prior, Madison was no stranger to long days at home, isolated from the school germs that could turn her illness into a critical condition with a single sneeze. When her friends couldn’t visit, her dogs were there. But at the hospital, they weren’t.
To view the multimedia release go to:
http://www.multivu.com/players/English/7835951-purina-family-pet-center-st-louis-childrens/
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Hunova, the first robotic gym for the rehabilitation and functional motor sense evaluation of lower limbs and trunk, has been officially launched in Genoa, Italy. The first 30 robots will be available from June in Europe and the USA. The technology was developed and patented at the IIT laboratories and has been launched on the market thanks to a 10 million euro investment from entrepreneur Sergio Dompè.
Hunova is a programmable robotic medical device that allows professionals in the geriatrics, neurology and sport rehabilitation field to cure and predict many neurological and orthopedic conditions. There are two main competitive advantages of this technology: Hunova is able to collect a significant amount of data on biomechanics, constantly monitoring the patient’s progress. Secondly, it provides direct support to the patient through a guiding robotic system, offering a wide range of rehabilitation protocols in the form of video games. It consists of two electromechanical platforms equipped with sensors, characterized by two degrees of freedom (feet and seat level). The device integrates the force sensors to adjust the interaction with the patient and a wireless sensor, which is placed on the patient’s trunk, allowing the physiotherapist to check the movement of the torso.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8108951-iit-movendo-launch-robot-hunova/
Sally Hansen continues to lead in innovation by introducing its new Color Therapy products: a nail polish, top coat, and nail & cuticle oil, inspired by women’s desire to wear beautiful color while simultaneously caring for their nails. Sally Hansen’s Color Therapy nail polish contains a patented micro-delivery system that delivers an argan oil-enriched formula, resulting in intensive nourishment and instant moisture for healthier-looking nails. The Color Therapy nail polish needs no base coat so the oil complex can directly contact the bare nail. 9 out of 10 women experienced a noticeable improvement in their natural nails after wearing the Color Therapy nail polish. Vibrant tones, available in three magnificent palettes, glide on for a radiant, shiny finish with up to 10 days of fade-proof, chip-resistant wear. The Color Therapy nail polish provides the ultimate color that cares while you wear, with everything needed to restore nails without sacrificing luminous color.
Complete your manicure with the Color Therapy top coat and nail & cuticle oil, both formulated with the same argan oil contained in the nail polish. The top coat provides an ultra-glossy finish for extended wear, and the nail & cuticle oil, the ultimate in nail therapy, instantly makes nails and cuticles look healthier, restored, and rejuvenated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7957151-sally-hansen-color-therapy-nail-polish/
